Sanofi is a global pharmaceuticals and vaccines company headquartered in France, and in the U.S. it trades as an American Depositary Receipt (SNY). The key takeaway from this quarter is that the composition of products driving sales is changing. Dupixent, the immunology treatment, posted a 37.6% increase from a year ago on broader prescribing across approved indications, with U.S. revenue alone reaching €3.899 billion (+42.8%). It is the first time quarterly revenue has surpassed €5 billion.

Adding to that, the recently launched pharma franchise grew 48.3%, providing an additional growth engine. Hemophilia treatment Altuviiio, rare-disease therapy Aubagio, and oncology drug Sarclisa led the way, and total U.S. revenue grew 33.5% at constant exchange rates. As revenue rose, business operating profit grew even faster, lifting the operating margin (28.4% of revenue) by 3.8 percentage points year over year. Improved product mix was complemented by one-off tailwinds such as the reversal of prior manufacturing provisions (over €200 million) following the approval of a subcutaneous formulation of Sarclisa.

Buoyed by the results, the company raised its 2026 full-year guidance. Revenue is expected to grow roughly 10% at constant exchange rates, with business EPS projected to grow slightly faster. A €1 billion share buyback was completed, and free cash flow for the quarter reached €2.670 billion, up 86.8% year over year.

The headline numbers on revenue and business profit were strong, but the "housekeeping costs" the market had to digest at the same time were sizable. The company decided not to advance its atopic dermatitis candidate amlitelimab to the global filing stage, and it also halted development of chronic obstructive pulmonary disease candidate itepekimab and inflammatory bowel disease candidate valziflocept. R&D expense included more than €200 million in cleanup costs tied to pipeline prioritization, and IFRS net profit fell 91.0% year over year due to impairment charges (approximately €952 million related to amlitelimab, among others). The gap between business profit and reported profit widened materially this quarter.

Vaccines also became a drag. Total vaccines revenue declined 4.7%, with flu and COVID vaccines in particular down 61.7%, reflecting both a high comparison base from a late prior-year season and weakness in the Southern Hemisphere. In China, lower birth rates weighed on first-dose vaccinations for polio, pertussis, and Hib, and total China revenue declined 4.9%.

The tone of the guidance raise is a double-edged sword. Given that first-half revenue already grew 15.7% at constant exchange rates, projecting roughly 10% for the full year embeds management's own premise of a "normalization (slowdown)" in second-half growth. That signals the first-half momentum may not carry over directly, and the market may be the first to read it that way.

CEO Paul Hudson characterized the second quarter as one of double-digit revenue growth and strong business EPS growth, explaining that the pharma new launches, M&A effects, and Dupixent drove the result. He raised the full-year outlook on the back of first-half performance but at the same time indicated that second-half growth would normalize, opening the door to an interpretation that "this may be the peak."

Among his early priorities as CEO, he cited diagnosing the challenges Sanofi faces and improving R&D and the pipeline, presenting pipeline prioritization and an executive committee reshuffle as first steps. He also redrew the medium-term picture of approximately €25 billion in Dupixent revenue by 2030 and roughly €10 billion from the pharma new-launch franchise (all at constant exchange rates). Because the message bundled a top-line upgrade with pipeline cleanup and a structural overhaul, the market appeared to weigh "what is being shed and where focus is shifting" more heavily than the strong results themselves.

On a day when revenue, business profit, and guidance all came in positive, the share price still fell — a sign the market was paying more attention to visibility on future growth than to the scorecard for the quarter. Even as Dupixent and the new-launch franchise delivered, the simultaneous combination of pipeline discontinuations, large impairment charges, and the normalization of second-half growth meant the report was not read as more positive than expected. The reversal of one-off provisions that supported business profit also leaves open the question of whether the earnings improvement is sustainable.

For beginner investors, it is worth keeping in mind that the ADR price moves with euro-denominated results, currency moves, and U.S. rate sentiment all at the same time. Rather than focusing on short-term swings, it is better to watch how much growth pace decelerates in the second half and whether the remaining post-cleanup pipeline actually converts into approvals and revenue.